Mizuho raised the firm’s price target on HCA Healthcare (HCA) to $520 from $505 and keeps an Outperform rating on the shares as part of its 2026 outlook for managed care and health facilities. The firm believes 2026 will be a “pivotal year” for managed care. The sector is at the end of a three-year negative underwriting cycle and margins should improve in commercial, Medicaid and Medicare over the next few years, the analyst tells investors in a research note. As a result, Mizuho is positive on managed care heading into 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare downgraded to Underweight from Equal Weight at Morgan Stanley
- Hospital stocks lower after Republicans propose Medicare funding cut
- HCA Healthcare price target raised to $431 from $412 at Wells Fargo
- HCA Healthcare Issues $3.25 Billion in Senior Notes
- HCA Healthcare price target raised to $525 from $485 at Jefferies
